Sakai, K, Kitagawa, T. An atypical case of tyrosinosis (1-para-hyroxyphenyllactic aciduria): I. Clinical and laboratory findings. Jikei Med J. 1957;2:1Google Scholar

Sakai, K, Kitagawa, T. An atypical case of tyrosinosis (1-para-hydroxyphenyllactic aciduria): II. A research on the metabolic block. Jikei Med J. 1957;2:11Google Scholar

Scott, CR. The genetic tyrosinemias. Am J Med Genet Part C. 2006;142:121–126CrossRefGoogle Scholar

King, LS, Trahms, C, Scott, CR. Tyrosinemia type 1 in GeneReviews at GeneTests: Medical Genetics Information Resource [database online; updated October 2008]. Copyright, University of Washington, Seattle. 1997–2007. Available at: http://www.genetests.org

DeBraekeleer, M, Larochelle, J. Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean. Am J Hum Genet. 1990;47:302–307Google Scholar

Mitchell, GA, Grompe, M, Lambert, M, Tanguay, RM. Hypertyrosinemia. Scriver, C., Beaudet, A, Sly, W., Valle, D., eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edition, McGraw-Hill, 1777–1805, 2001Google Scholar

Mitchell, G, Larochelle, J, Lambert, M, Michaud, J, Grenier, A, Ogier, H, Gauthier, M, Lacroix, J, Vanasse, M, Larbrisseau, A, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med. 1990;322:432–437CrossRefGoogle ScholarPubMed

Spronsen, FJ, Thomasse, Y, Smit, GPA, Leonard, JV, Clayton, PT, Fidler, V, Berger, R, Heymans, HAS. Hereditary tyrosinemia type I: A new clinical classification with difference in prognosis on dietary treatment. Hepatology. 1994;20:1187–1191CrossRefGoogle ScholarPubMed

Arora, N, Stumper, O, Wright, J, Kelly, DA, McKiernan, PJ. Cardiomyopathy in tyrosinemia type I is common but usually benign. J Inherit Metab Dis. 2006;29:54–57CrossRefGoogle ScholarPubMed

Holme, E, Lindstedt, S. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). J Inherit Metab Dis. 1998;21:507–517CrossRefGoogle Scholar

Sze, YK, Dhawan, A, Taylor, RM, Bansal, S, Mieli-Vergani, G, Rela, M, Heaton, N. Pediatric liver transplantation for metabolic liver disease: Experience at King's College Hospital. Transplantation. 2009;87:87–93CrossRefGoogle ScholarPubMed

Kayler, LK, Rasmussen, CS, Dykstra, DM, Punch, JD, Rudich, SM, Magee, JC, Maraschio, MA, Arenas, JD, Campbell, DA, Merion, RM. Liver transplantation in children with metabolic disorders in the United States. Am J Transplant. 2003;3:334–339CrossRefGoogle ScholarPubMed

Mohan, N, McKiernan, P, Preece, MA, Green, A, Buckels, J, Mayer, AD, Kelly, DA. Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr. 1999;158(Suppl 2):S49–S54CrossRefGoogle ScholarPubMed

Allard, P, Grenier, A, Korson, MS, Zytkovicz, TH. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: Analysis of succinylacetone extracted from dried blood spots. Clin Biochem. 2004;37:1010–1015CrossRefGoogle ScholarPubMed

Turgeon, C, Magera, MJ, Allard, P, Tortorelli, S, Gavrilov, D, Oglesbee, D, Raymond, K, Rinaldo, P, Matern, D. Combined newborn screening for succinylacetone, amino acids, and acylcarnitine in dried blood spots. Clin Chem. 2008;54:657–664CrossRefGoogle ScholarPubMed

Lindblad, B, Lindstedt, S, Steen, G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA. 1977;74:4641–4645CrossRefGoogle ScholarPubMed

Grompe, M. The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis. 2001;21:563–571CrossRefGoogle ScholarPubMed

Jorquera, R, Tanguay, RM. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. Biochem Biophys Res Commun. 1997;232:42–48CrossRefGoogle ScholarPubMed

Phaneuf, D, Labelle, Y, Berube, D, Arden, K, Cavenee, W, Gagne, R, Tanguay, RM. Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: Assignment of the gene to chromosome 15. Am J Hum Genet. 1991;48:525–535Google ScholarPubMed

,The Human Gene Mutation Database at the Institute of Medical Genetics in Cardiff. Available at: http://www.hgmd.cf.ac.uk/ac/index.php

Poudrier, J, St-Louis, M, Lettre, F, Gibson, K, Prevost, C, Larochelle, J, Tanguay, RM. Frequency of the IVS12+5G➔A splice mutation of the fumarylacetoacetate hydrolase gene in carriers of hereditary tyrosinemia in the French Canadian population of Saguenay-Lac-St.-Jean. Prenat Diagn. 1996;16:59–643.0.CO;2-D>CrossRefGoogle ScholarPubMed

Arranz, J, Pinol, F, Kozak, L, Perez-Cerda, C, Cormand, B, Ugarte, M, Riudor, E. Splicing mutations, mainly IVS6–1(G4T), account for 70% of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients. Hum Mutat. 2002;20:180–188CrossRef

Elpeleg, ON, Shaag, A, Holme, E, Zughayar, G, Ronen, S, Fisher, D, Hurvitz, H. Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I. Hum Mutat. 2002;19(1):80–81CrossRefGoogle ScholarPubMed

St-Louis, M, Leclerc, B, Laine, J, Salo, MK, Holmberg, C, Tanguay, RM. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. Hum Mol Genet. 1994;3:69–72CrossRefGoogle ScholarPubMed

Poudrier, J, Lettre, F, Scriver, CR, Larochelle, J, Tanguay, RM. Different clinical forms of hereditary tyrosinemia (type I) in patients with identical genotypes. Mol Genet Metab. 1998;64:119–125CrossRefGoogle ScholarPubMed

Kvittingen, EA, Rootwelt, H, Berger, R, Brandtzaeg, P. Self-induced correction of the genetic defect in tyrosinaemia type I. J Clin Invest. 1994;94:1657–1661CrossRefGoogle Scholar

Rootwelt, H, Brodtkorb, E, Kvittingen, EA. Identification of a frequent pseudodeficiency mutation in the fumarylacetoacetase gene, with implications for diagnosis of tyrosinemia type 1. Am J Hum Genet. 1994;55:1122–1127Google Scholar

Phornphutkul, C, Introne, WJ, Perry, MB, Bernardini, I, Murphey, M, Fitzpatrick, DL, Anderson, PD, Huizing, M, Anikster, Y, Gerber, LH, Gahl, WA. Natural history of alkaptonuria. N Engl J Med. 2002;347:2111–2121CrossRefGoogle ScholarPubMed

Goicoechea de Jorge, E, Lorda, I, Gallardo, ME, Perez, B, Perez de Ferran, C, Mendoza, H, Rodriguez de Cordoba, S. Alkaptonuria in the Dominican Republic: Identification of the founder AKU mutation and further evidence of mutation hot spots in the HGO gene. J Med Genet. 2002;39:e40CrossRefGoogle ScholarPubMed

Srsen, S, Cisaric, F, Pasztor, L, Harmecko, L. Alkaptonuria in the Trencin district of Czechoslovakia. Am J Med Genet. 1978;2:159–166CrossRefGoogle ScholarPubMed

Perry, MB, Suwannarat, P, Furst, GP, Gahl, WA, Gerber, LH. Musculoskeletal findings and disability in alkaptonuria. J Rheumatol. 2006;33:2280–2285Google ScholarPubMed

Haas, V, Carbasius Weber, EC, Klerk, JBC, Bakker, HD, Smit, GPA, Huijbers, WAR, Duran, M, Poll-The, BT. The success of dietary protein restriction in alkaptonuria patients is age-dependent. J Inherit Metab Dis. 1998;21:791–798CrossRefGoogle ScholarPubMed

Wolff, JA, Barshop, B, Nyhan, WL, Leslie, J, Seegmiller, JE, Gruber, H, Garst, M, Winter, S, Michals, K, Matalon, R. Effects of ascorbic acid in alkaptonuria: Alterations in benzoquinone acetic acid and an ontogenic effect in infancy. Pediatr Res. 1989;26:140–144CrossRefGoogle ScholarPubMed

Spencer, JMF, Maxime, CL, Gibbons, H, Sharp, RJ, Carr, AJ, Athanasou, NA. Arthroplasty for ochronotic arthritis. Acta Orthop Scand. 2004;75:355–358CrossRefGoogle ScholarPubMed

Introne, WJ, Phornphutkul, C, Bernardini, I, McLaughlin, K, Fitzpatrick, D, Gahl, WA. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation. Mol Genet Metab. 2002;77:136–142CrossRefGoogle ScholarPubMed

Kobak, AC, Oder, G, Kobak, S, Argin, M, Inal, V. Ochronotic arthropathy: Disappearance of alkaptonuria after liver transplantation for hepatitis B-related cirrhosis. J Clin Rheumatol. 2005;11:323–325CrossRefGoogle ScholarPubMed

Fernandez-Canon, JM, Granadino, B, Beltran-Valero de Bernabe, D, Renedo, M, Fernandez-Ruiz, E, Penalva, MA, Rodriguez de Cordoba, S. The molecular basis of alkaptonuria. Nature. 1996;14:19–24Google ScholarPubMed

Titus, GP, Mueller, HA, Burgner, J, Rodriguez de Cordoba, S, Penalva, MA, Timm, . Crystal structure of human homogentisate dioxygenase. Nat Struct Biol. 2000;7:542–546.Google ScholarPubMed

Kayser, MA, Introne, W, Gahl, WA. Valle, Alkaptonuria., Beaudet, Vogelstein, Kinzler, Antonarakis, Ballabio, Scriver, Childs, , and Sly, , eds. The Online Metabolic & Molecular Bases of Inherited Disease. Updated November 2007. Available at: http://www.ommbid.com/

Hall, MG, Wilks, MF, Provan, WM, Eksborg, S, Lumholtz, B. Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol. 2001;52:169–177CrossRefGoogle ScholarPubMed

Lock, EA, Ellis, MK, Gaskin, P, Robinson, M, Auton, TR, Provan, WM, Smith, LL, Prisbylla, MP, Mutter, LC, Lee, DL. From toxicological problem to therapeutic use: The discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. J Inherit Metab Dis. 1998;21:498–506CrossRefGoogle Scholar

,Swedish Orphan International AB. Orfadin package insert.

Lock, EA, Gaskin, P, Ellis, MK, Provan, WM, Robinson, M, Smith, LL, Prisbylla, MP, Mutter, LC. Tissue distribution of 2-(2-nitro-4-trifluoromethylbenzoyl) cyclohexane-1–3-dione (NTBC): Effect on enzymes involved in tyrosine catabolism and relevance to ocular toxicity in the rat. Toxicol Appl Pharmacol. 1996;141:439–447CrossRefGoogle ScholarPubMed

Szczeciński, P, Lamparska, D, Gryff-Keller, A, Gradowska, W. Identification of 2-[2-nitro-4-(trifluoromethyl)benzoyl]-cyclohexane-1,3-dione metabolites in urine of patients suffering from tyrosinemia type I with the use of 1H and 19F NMR spectroscopy. Acta Biochim Pol. 2008;55:749–752Google ScholarPubMed

Santra, S, Baumann, U. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1. Expert Opin Pharmacother. 2008;9:1229–1236CrossRefGoogle ScholarPubMed

Kavana, M, Moran, GR. Interaction of (4-hydroxyphenyl)pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl)benzoyl]-1,3-cyclohexanedione. Biochemistry. 2003;42:10238–10245CrossRefGoogle ScholarPubMed

Ellis, MK, Whitfield, AC, Gowans, , Auton, TR, Provan, WM, Lock, EA, Smith, LL. Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione. Toxicol Appl Pharmacol. 1995;133:12–19CrossRefGoogle ScholarPubMed

Lindstedt, S, Holme, E, Lock, EA, Hjalmarson, O, Strandvik, B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992;340:813–817CrossRefGoogle ScholarPubMed

Suwannarat, P, O'Brien, K, Perry, MB, Sebring, N, Bernardini, I, Kaiser-Kupfer, MI, Rubin, BI, Tsilou, E, Gerber, LH, Gahl, WA. Use of nitisinone in patients with alkaptonuria. Metabolism. 2005;54:719–728CrossRefGoogle ScholarPubMed

Ahmad, S, Teckman, JH, Lueder, GT. Corneal opacities associated with NTBC treatment. Am J Ophthalmol. 2002;134:266–268CrossRefGoogle ScholarPubMed

Gissen, P, Preece, MA, Willshaw, HA, McKiernan, PJ. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC. J Inherit Metab Dis. 2003;26:13–16CrossRefGoogle ScholarPubMed

Masurel-Paulet, A, Poggi-Bach, J, Rolland, MO, Bernard, O, Guffon, N, Dobbelaere, D, Sarles, J, de Baulny, HO, Touati, G. NTBC treatment in tyrosinaemia type I: Long-term outcome in French patients. J Inherit Metab Dis. 2008;31:81–87CrossRefGoogle ScholarPubMed

Spronsen, FJ, Berger, R, Smit, GP, Klerk, JB, Duran, M, Bijleveld, CM, Faassen, H, Slooff, MJ, Heymans, HS. Tyrosinaemia type I: Orthotopic liver transplantation as the only definitive answer to a metabolic as well as an oncological problem. J Inherit Metab Dis. 1989;12(Suppl 2):339–342CrossRefGoogle ScholarPubMed

Holme, E, Lindstedt, S. Nontransplant treatment of tyrosinemia. Clin Liver Dis. 2000;4:805–814CrossRefGoogle ScholarPubMed

Spronsen, FJ, Bijleveld, CM, Maldegem, BT, Wijburg, FA. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro-methylbenzoyl)-1,3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr. 2005;40:90–93CrossRefGoogle Scholar

Luijerink, MC, Jacobs, SM, Beurden, EA, Koornneef, LP, Klomp, LW, Berger, R, Berg, IE. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). J Hepatol. 2003;39:901–909CrossRefGoogle Scholar

Koelink, CJ, Hasselt, P, Ploeg, A, Heuvel-Eibrink, MM, Wijburg, FA, Bijleveld, CM, van Spronsen, FJ. Tyrosinemia type I treated by NTBC: How does AFP predict liver cancer?Mol Genet Metab. 2006;89:310–315CrossRefGoogle ScholarPubMed

Santra, S, Preece, MA, Hulton, SA, McKiernan, PJ. Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis. 2008;31:399–402CrossRefGoogle ScholarPubMed

Schlump, JU, Perot, C, Ketteler, K, Schiff, M, Mayatepek, E, Wendel, U, Spiekerkoetter, U. Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment. J Inherit Metab Dis. 2008 [Epub ahead of print]

André, N, Roquelaure, B, Jubin, V, Ovaert, C. Successful treatment of severe cardiomyopathy with NTBC in a child with tyrosinaemia type I. J Inherit Metab Dis. 2005;28:103–106CrossRefGoogle Scholar